Content
Search
Navigation
Sitemap
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
Achilles Therapeutics
Anaveon
SwanBio Therapeutics
Freeline Therapeutics
Quell Therapeutics
Pre-clinical companies
Overview
Resolution Therapeutics
Purespring Therapeutics
Clade Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Syncona investments
Overview
Forcefield Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Portfolio data
Browse all portfolio data news
Search
Latest portfolio data news
Show news from
all companies
all companies
all Late-stage clinical companies companies
Autolus Therapeutics
all Clinical companies companies
Achilles Therapeutics
Anaveon
Freeline Therapeutics
all Pre-clinical companies companies
Clear filters
25.10.23
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
Clinical companies
Freeline Therapeutics
16.10.23
Anaveon announces poster presentation at the 2023 European Society for Medical Oncology Annual Meeting
Clinical companies
Anaveon
04.10.23
Freeline Announces Positive Initial Clinical Data
Clinical companies
Freeline Therapeutics
05.09.23
Autolus Therapeutics announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood
Late-stage clinical companies
Autolus Therapeutics
06.07.23
Autolus Therapeutics announces a publication in Nature Medicine on obe-cel in Pediatric Acute Lymphoblastic Leukemia
Late-stage clinical companies
Autolus Therapeutics
27.06.23
Autolus Therapeutics announces publication in Cancer Immunology Research
Late-stage clinical companies
Autolus Therapeutics
Load more
Close menu
About us
View this section
View this section
Who we are
Our model
Our investment process
Our purpose, culture and values
Our history
Our people
View this section
View this section
Board of Directors
Portfolio
View this section
View this section
Portfolio data
Late-stage clinical companies
Overview
Autolus Therapeutics
Beacon Therapeutics
Clinical companies
Overview
Achilles Therapeutics
Anaveon
SwanBio Therapeutics
Freeline Therapeutics
Quell Therapeutics
Pre-clinical companies
Overview
Resolution Therapeutics
Purespring Therapeutics
Clade Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Syncona investments
Overview
Forcefield Therapeutics
Previous investments
Overview
Gyroscope Therapeutics
Blue Earth
Nightstar
Neogene Therapeutics
14MG
Azeria Therapeutics
Sustainability
View this section
View this section
Message from CEO, SIML
Our approach to sustainability reporting
Our social impact
Responsible investor and partner
Overview
Responsible investment process
A responsible partner
Inspiring and empowering our people
Responsible and ethical business
Overview
Environment
Syncona’s approach to charity
Overview
The Syncona Foundation
Sustainability policies
News and insights
View this section
View this section
News
Insights & articles
Publications & presentations
Investors
View this section
View this section
KPIs
Results and presentations
RNS and inside information
Share price centre
Governance
Overview
Our Committees
How we communicate with our stakeholders
Regulatory publications
Financial calendar
Analysts and advisers
Shareholder information
Overview
Shareholder documents
FAQs
Contact
Search
Search